Table 1.
Baseline characteristics of participants according to randomized controlled trial (RCT) arm and of nonparticipants.
|
|
CAUa (n=77) | Return of PROb results (n=74) | Return of PRO results + living with lymphoma (n=76) | P valuec | Total RCT participants (n=227) | Nonparticipants (n=666) | P valued | |||||||||||||
| Sociodemographic characteristics | ||||||||||||||||||||
|
|
Age at time of questionnaire (years), mean (SD) | 61.3 (12.9) | 60.0 (13.4) | 60.8 (14.0) | .83 | 60.7 (13.4) | 65.3 (15.7) | <.001 | ||||||||||||
|
|
Sex, n (%) | .73 |
|
|
<.001 | |||||||||||||||
|
|
|
Male | 53 (68.8) | 55 (74.3) | 53 (69.7) |
|
161 (70.9) | 377 (56.6) |
|
|||||||||||
|
|
|
Female | 24 (31.2) | 19 (25.7) | 23 (30.3) |
|
66 (29.1) | 289 (43.4) |
|
|||||||||||
|
|
Educational levele, n (%) | .71 |
|
|
—g | |||||||||||||||
|
|
|
Low | 1 (1.3) | 2 (2.7) | 3 (3.9) |
|
6 (2.6) | N/Af |
|
|||||||||||
|
|
|
Medium | 33 (42.9) | 38 (51.4) | 35 (46.1) |
|
106 (46.7) | N/A |
|
|||||||||||
|
|
|
High | 42 (54.5) | 34 (45.9) | 38 (50) |
|
114 (50.2) | N/A |
|
|||||||||||
|
|
Partner (yes), n (%) | 62 (80.5) | 65 (87.8) | 63 (82.9) | .46 | 190 (83.7) | N/A | — | ||||||||||||
| Clinical characteristics | ||||||||||||||||||||
|
|
Months since diagnosis: mean (SD) | 14.0 (3.1) | 14.0 (3.6) | 13.9 (3.0) | .94 | 14.0 (3.2) | 14.0 (3.5) | .80 | ||||||||||||
|
|
Cancer type, n (%) | |||||||||||||||||||
|
|
|
Hodgkin lymphoma | 10 (12.9) | 8 (10.8) | 9 (11.8) | .99 | 27 (11.9) | 75 (11.3) | .95 | |||||||||||
|
|
|
NHL-HGh | 41 (53.2) | 41 (55.4) | 42 (55.3) |
|
125 (55.1) | 359 (53.9) |
|
|||||||||||
|
|
|
NHL-LGi | 18 (23.4) | 19 (25.7) | 19 (25) |
|
56 (24.7) | 169 (25.4) |
|
|||||||||||
|
|
|
CLLj | 8 (10.4) | 6 (8.1) | 6 (7.9) |
|
19 (8.4) | 63 (9.5) |
|
|||||||||||
|
|
Primary treatment, n (%) | .10 |
|
|
.13 | |||||||||||||||
|
|
|
Active surveillance | 23 (29.9) | 18 (24.3) | 12 (15.8) |
|
53 (23.3) | 199 (28.5) |
|
|||||||||||
|
|
|
Received active treatment | 52 (67.5) | 56 (75.7) | 64 (84.2) |
|
172 (75.8) | 458 (68.8) |
|
|||||||||||
|
|
|
Chemotherapy | 37 (48.1) | 46 (62.2) | 54 (71.1) |
|
137 (60.4) | 357 (54) |
|
|||||||||||
|
|
|
Radiotherapy | 5 (6.5) | 4 (5.4) | 3 (3.9) |
|
12 (5.3) | 60 (8.1) |
|
|||||||||||
|
|
|
Stem cell transplantation | 8 (10.4) | 3 (4.1) | 3 (3.9) |
|
14 (6.2) | 4 (0.6) |
|
|||||||||||
|
|
|
Other | 2 (2.6) | 3 (4.1) | 4 (5.3) |
|
9 (3.9) | 37 (5.6) |
|
|||||||||||
|
|
Ann Arbor stage | .81 |
|
|
.30 | |||||||||||||||
|
|
|
Stage I, n (%) | 6 (7.8) | 8 (10.8) | 15 (19.7) |
|
29 (12.8) | 112 (16.8) |
|
|||||||||||
|
|
|
Stage II, n (%) | 8 (10.4) | 13 (17.6) | 15 (19.7) |
|
36 (15.8) | 95 (14.3) |
|
|||||||||||
|
|
|
Stage III, n (%) | 11 (14.3) | 9 (12.2) | 10 (13.2) |
|
30 (13.2) | 97 (14.6) |
|
|||||||||||
|
|
|
Stage IV, n (%) | 30 (38.9) | 30 (40.5) | 26 (34.2) |
|
86 (37.9) | 194 (29.1) |
|
|||||||||||
|
|
|
Not determined (CLL) or missing, n (%) | 22 (28.6) | 14 (18.9) | 10 (13.2) |
|
46 (20.3) | 168 (25.2) |
|
|||||||||||
|
|
|
Number of self-reported comorbidities: mean (SD) | 1.3 (1.2) | 1.2 (1.1) | 1.0 (1.0) | .22 | 1.1 (1.1) | N/A |
|
|||||||||||
| Psychological characteristics, n (%) | ||||||||||||||||||||
|
|
Psychological distress | 17 (22.1) | 9 (12.2) | 8 (10.5) | .09 | 34 (14.9) | N/A | — | ||||||||||||
aCAU: care as usual.
bPRO: patient-reported outcome.
cReports comparisons between the intervention arms and the care as usual arm.
dReports comparisons between randomized controlled trial participants and nonparticipants.
eEducation levels were low=none or primary school; medium=lower general secondary education or vocational training; or high=preuniversity education or high-level vocational training or university.
fN/A: not applicable.
gNot available.
hNHL-HG: high-grade non-Hodgkin lymphoma.
iNHL-LG: low-grade non-Hodgkin lymphoma.
jCLL: chronic lymphocytic leukemia.